Finance

Lists
Why is ALK-B up 5,31%?
Dive Deeper
ALK-B:CPH
ALK-Abello A/S
218,00 DKK
+5,31%
(+11,00) 1D
7 ოქტ, 17:00:00 GMT+2  ·   DKK
All symbols
SymbolPriceChange% Change
Generating top insights for ALK-B...
Open
213,20 DKK
High
219,20 DKK
Low
211,00 DKK
Mkt. cap
40,98 მლრდ.
Avg. vol.
232,66 ათ.
Volume
336,63 ათ.
52-wk high
271,40 DKK
52-wk low
191,80 DKK
Shares outstanding
202,57 მლნ.
No. of employees
3 ათ.
Open
213,20 DKK
High
219,20 DKK
Low
211,00 DKK
Mkt. cap
40,98 მლრდ.
Avg. vol.
232,66 ათ.
Volume
336,63 ათ.
52-wk high
271,40 DKK
52-wk low
191,80 DKK
Shares outstanding
202,57 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Investing.com Nigeria
Investing.com Nigeria
·
11 საათის წინ
ALK raises 2026 outlook on strong tablet sales growth By Investing.com
Profile
ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy. It is one of the world's largest makers of allergy immunotherapy products with 67% of its revenue coming from sales in Europe. Wikipedia
About ALK-Abello A/S
CEOპიტერ ჰალინგ
Employees2,77 ათ.
Founded1923
Headquarters-
SectorPharmaceutical industry
Websitealk.net
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,53 მლრდ.
1,73 მლრდ.
1,77 მლრდ.
1,80 მლრდ.
Cost of goods sold
487,00 მლნ.
543,00 მლნ.
543,00 მლნ.
600,00 მლნ.
Cost of revenue
487,00 მლნ.
543,00 მლნ.
543,00 მლნ.
600,00 მლნ.
Research and development expenses
145,00 მლნ.
189,00 მლნ.
151,00 მლნ.
168,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
475,00 მლნ.
605,00 მლნ.
507,00 მლნ.
582,00 მლნ.
Operating expense
620,00 მლნ.
793,00 მლნ.
658,00 მლნ.
750,00 მლნ.
Total operating expenses
1,11 მლრდ.
1,34 მლრდ.
1,20 მლრდ.
1,35 მლრდ.
Operating income
423,00 მლნ.
397,00 მლნ.
570,00 მლნ.
445,00 მლნ.
Other non operating income
-
-
-
-
EBT including unusual items
419,00 მლნ.
393,00 მლნ.
583,00 მლნ.
452,00 მლნ.
EBT excluding unusual items
419,00 მლნ.
403,00 მლნ.
583,00 მლნ.
452,00 მლნ.
Income tax expense
105,00 მლნ.
127,00 მლნ.
146,00 მლნ.
113,00 მლნ.
Effective tax rate
25,06%
32,32%
25,04%
25,00%
Other operating expenses
-
-1,00 მლნ.
-
-
Net income
314,00 მლნ.
266,00 მლნ.
437,00 მლნ.
339,00 მლნ.
Net profit margin
20,52%
15,35%
24,68%
18,89%
Earnings per share
1,40
1,20
2,00
1,50
Interest and investment income
-
28,00 მლნ.
13,00 მლნ.
7,00 მლნ.
Interest expense
-4,00 მლნ.
-6,00 მლნ.
-
-
Net interest expenses
-4,00 მლნ.
22,00 მლნ.
13,00 მლნ.
7,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
510,00 მლნ.
400,00 მლნ.
654,00 მლნ.
531,00 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები